We therefore asked whether the compromised viability of the EZH2GOF DLBCL cells achieved by an EZH2 inhibitor can also be obtained using an HDAC1,2-selective inhibitor. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.